1. A method for performing a handover from a source cell to a target cell by a User Equipment (UE) in a mobile communication system, the method comprising:
sending a measurement report on received signal strengths of adjacent cells, to an Node B of the source cell;
sending, to the Node B of the source cell, a status report including a sequence number of successfully received packet data and a sequence number of missing packet data; and
upon a receipt of a handover command from the Node B of the source cell, performing a handover.
2. The method of claim 1, further comprising:
after sending the measurement report, receiving a handover preparation request from the Node B of the source cell; and
sending the status report after receiving the handover preparation request.
3. The method of claim 1, further comprising:
after sending the measurement report, determining whether the measurement report satisfies a handover condition predefined between the UE and the Node B of the source cell; and
when the measurement report satisfies the handover condition, sending the status report
4. A User Equipment (UE) apparatus for performing a handover from a source cell to a target cell in a mobile communication system, the apparatus comprising:
a measurement controller for measuring received signal strengths of adjacent cells;
a radio resource controller for generating a message using the measurement result received from the measurement controller, and sending the generated message to an Node B of the source cell; and
a radio link controller for, upon a receipt of a status report command from the radio resource controller, generating a status report message before performing a handover to the target cell, and sending the generated status report message to the Node B of the source cell.
5. The UE apparatus of claim 4, wherein the measurement controller determines whether the measurement result satisfies a handover condition predefined between the UE and the Node B of the source cell, and sends the determination result to the radio resource controller; and
wherein the radio resource controller sends the status report command to the radio link controller according to the determination result of the measurement controller.
6. The UE apparatus of claim 4, wherein the radio resource controller sends the status report command to the radio link controller upon a receipt of a handover preparation request from the Node B of the source cell.
7. The UE apparatus of claim 4, wherein the status report message includes a sequence number of successfully received packet data and a sequence number of missing packet data.
8. A method for sending a buffer status report by a User Equipment (UE) in a mobile communication system, the method comprising:
if a measurement report of a first type having a high handover-causing possibility occurs, sending a request for a resource allocation for a buffer status report to an Node B;
sending a buffer status report including information on retransmission-required packet data over resources allocated by the request; and
sending a measurement report and a downlink status report and retransmitting the retransmission-required packet data over resources allocated according to the buffer status report.
9. The method of claim 8, wherein the buffer status report further comprises a size of a downlink status report configured at a transmission time of the buffer status report, and a size of data stored in a buffer of a radio bearer group to which the measurement report of the first type belongs.
10. The method of claim 9, further comprising:
if the measurement report of the first type occurs, setting a priority of the downlink status report and the retransmission-scheduled data to a predetermined priority;
wherein the buffer status report further includes an identifier of a radio bearer group corresponding to a priority to be applied to the downlink status report and the retransmission-scheduled data.
11. A User Equipment (UE) apparatus for sending a buffer status report to an Node B of a source cell in a mobile communication system, the apparatus includes:
a measurement controller for measuring received signal strengths of adjacent cells;
a radio resource controller for generating a message using a measurement result received from the measurement controller, and sending the generated message to the Node B of the source cell;
a radio link controller for generating a status report message upon receipt of a status report command from the radio resource controller before performing a handover to a target cell, and sending the generated status report message to the Node B of the source cell;
a buffer status report controller for starting a buffer status report procedure under a control of the radio resource controller if a measurement report of a first type having a high handover-causing possibility occurs, and configuring a buffer status report including information on retransmission-scheduled data; and
a physical layer for sending the configured buffer status report to the Node B.
12. The UE apparatus of claim 11, wherein the physical layer sends a measurement report and a downlink status report and retransmits the retransmission-required packet data over resources allocated according to the buffer status report.
13. The UE apparatus of claim 12, wherein the buffer status report further includes a size of a downlink status report configured at a transmission time of the buffer status report, and a size of data stored in a buffer of a radio bearer group to which the measurement report of the first type belongs.
14. The UE apparatus of claim 13, wherein if the measurement report of the first type occurs, the radio link controller sets a priority of the downlink status report and the retransmission-scheduled data to a predetermined priority; and
wherein the buffer status report further includes an identifier of a radio bearer group corresponding to a priority to be applied to the downlink status report and the retransmission-scheduled data.
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.
1. A composition comprising:
a) an adipose tissue;
b) a silk fibroin material;
c) a compound having the structure of formula VI
wherein each dashed line represents the presence or absence of a bond;
Z2 and Z3 are independently CH or N;
Z1, Z4, Z5, and Z6 are each independently CR9, CHR9, NH, O, or S;
A is \u2014(CH2)6\u2014, or cis \u2014CH2CH\u2550CH\u2014(CH2)3\u2014, wherein 1 or 2 carbons may be substituted with S or O; or A is \u2014(CH2)m\u2014Ar\u2014(CH2)o\u2014 wherein Ar is optionally substituted aryl or optionally substituted heteroaryl, the sum of m and o is from 1, 2, 3, or 4, and wherein one CH2 may be substituted with S or O;
R8 is H, hydrocarbyl, or hydrocarbyl-OH;
R9 is independently H, C1-6 alkyl, OH, F, Cl, Br, I, or O;
J is C1-6 alkyl, C1-6\u2014O-alkyl, C\u2550O, or CHOH;
E is C1-12 alkyl, R10, or \u2014Y\u2014R10 wherein Y is CH2, S, or O, and R10 is optionally substituted aryl or optionally substituted heteroaryl; and n is 0 or 1,
a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable amine salt thereof.
2. The composition of claim 1, wherein the compound has the structure of formula VII
wherein each dashed line represents the presence or absence of a bond;
Z2 is CH or N;
Z5 is CH2, NH, O, or S;
Z7 is CH2, O, or S;
R8 is H, C1-6 hydrocarbyl, or C1-6 hydrocarbyl-OH;
R9 and R11 are independently C1-6 alkyl, OH, F, Cl, Br, I, or O; and
R12 is H, OH, O, F, Cl, Br, I, C1-4\u2014O-alkyl, C1-4 haloalkyl, or aryl,
a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable amine salt thereof.
3. The composition of claim 1, wherein the compound has the structure of formula VIII
wherein each dashed line represents the presence or absence of a bond;
Z2 is CH or N;
Z5 is CH2, NH, O, or S;
Z7 and Z8 are independently CH2, O, or S;
R8 is H, C1-6 hydrocarbyl, or C1-6 alkyl-OH;
R9 and R11 are independently C1-6 alkyl, OH, F, Cl, Br, I, or O; and
R12 is H, OH, O, F, Cl, Br, I, C1-4\u2014O-alkyl, C1-4 haloalkyl, or aryl,
a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable amine salt thereof.
4. The composition of claim 1, wherein the compound is
a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable amine salt thereof.
5. The composition of claim 1, wherein the compound is incorporated into a drug delivery platform comprising a biodegradable polymer matrix.
6. The composition of claim 1, wherein the silk fibroin material is in the form of a silk hydrogel, a silk film, a silk scaffold, a silk sheet, a silk porous material, a silk fiber, or any combination thereof.
7. The composition of claim 1, wherein the silk fibroin material is substantially sericin free.
8. A method of treating a soft tissue condition of an individual, the method comprising the step of administering to a site of the soft tissue condition a composition comprising adipose tissue, a silk fibroin material, and a compound, wherein the compound is according to claim 1, and wherein administration of the compound promotes formation of a blood supply sufficient to support the transplanted tissue, thereby treating the soft tissue site.
9. The method of claim 8, wherein the soft tissue condition is a breast tissue condition, a facial tissue condition, a neck condition, a skin condition, an upper arm condition, a lower arm condition, a hand condition, a shoulder condition, a back condition, a torso including abdominal condition, a buttock condition, an upper leg condition, a lower leg condition including calf condition, a foot condition including plantar fat pad condition, an eye condition, a genital condition, or a condition effecting another body part, region or area.
10. The method of claim 9, wherein the breast tissue condition is a breast imperfection, a breast defect, a breast augmentation, or a breast reconstruction.
11. The method of claim 9, wherein the facial tissue condition is a facial imperfection, a facial defect, a facial augmentation, or a facial reconstruction.
12. The method of claim 9, wherein the facial soft tissue condition is a dermal divot, a sunken cheek, a thin lip, a nasal imperfection or defect, a retro-orbital imperfection or defect, a facial fold, a facial line, a facial wrinkle, or other size, shape or contour imperfection or defect of the face.
13. The method of claim 8, wherein the soft tissue condition is urinary incontinence, fecal incontinence, or gastroesophageal reflux disease (GERD).
14. A method of treating a soft tissue condition of an individual, the method comprising the steps of
a) administering adipose tissue to a site of the soft tissue condition;
b) administering a silk fibroin material to the site of the soft tissue condition; and
c) administering a composition to the site of the soft tissue condition, the composition according to claim 1, wherein administration of the compound promotes formation of a blood supply sufficient to support the transplanted tissue, thereby treating the soft tissue site.
15. The method of claim 14, wherein the silk fibroin material is administered at the same time as, before, or after the compound is administered.
16. The method of claim 14, wherein the soft tissue condition is a breast tissue condition, a facial tissue condition, a neck condition, a skin condition, an upper arm condition, a lower arm condition, a hand condition, a shoulder condition, a back condition, a torso including abdominal condition, a buttock condition, an upper leg condition, a lower leg condition including calf condition, a foot condition including plantar fat pad condition, an eye condition, a genital condition, or a condition effecting another body part, region or area.
17. The method of claim 16, wherein the breast tissue condition is a breast imperfection, a breast defect, a breast augmentation, or a breast reconstruction.
18. The method of claim 16, wherein the facial tissue condition is a facial imperfection, a facial defect, a facial augmentation, or a facial reconstruction.
19. The method of claim 16, wherein the facial soft tissue condition is a dermal divot, a sunken cheek, a thin lip, a nasal imperfection or defect, a retro-orbital imperfection or defect, a facial fold, a facial line, a facial wrinkle, or other size, shape or contour imperfection or defect of the face.
20. The method of claim 14, wherein the soft tissue condition is urinary incontinence, fecal incontinence, or gastroesophageal reflux disease (GERD).